We are seeing an influx of several smart-enabled devices, such as inhalers and potentially injectables (eg, insulin pens), that may be quite similar to Abilify M圜ite, enabling tracking of adherence performance in patients.
Other questions that have not yet been answered is what role will pharmacists play with these type of devices and other smart-enabled medications coming to market.
Ambify setup skin#
Interestingly, almost 13% of patients complained of skin rashes associated with the patch in clinical trials. One question I have is how do patients get additional patches. Each box comes 7 patches, so I assume this is to make up for any that fall off or do not adhere correctly. This patch can remain in place up to 7 days, after which it must be replaced. So, how do these patches work? Users must clean the area and then place the patch on the left side of the abdomen just below the rib cage or basically, over the stomach. It is not hard to envision this product being rolled out to other medications for high-risk diseases, such as infectious diseases that require close adherence, or high-cost medications. Nonadherence to treatment by patients with several mental health diseases is common, so the concept as an early warning system to identify such individuals makes clinical sense. Providers who have access to the information can be alerted when the patient is not taking their medication. Patients may elect to share that data with whomever they want.
Ambify setup download#
Essentially, patients must download the app, attach the sensor to their abdomens, and when they take their medication, it keeps track on their smartphones.
This useful infographic 3 from the Abilify M圜ite page shows how it works. With the product coming to market, it is a good time to find out how the prescription for this product will come through, if it will be a specialty medication, and who is responsible for helping the patient set up the device and application. It says that the ability of Abilify M圜ite to improve patient compliance or modify aripiprazole dosage has not been established, and its use to track drug ingestion in real time or during an emergency is not recommended, because detection may be delayed or not occur. The issue though, as seen in the prescribing information, 2 is that M圜ite is not indicated to improve adherence under limitations of use. This has been remedied, leading to the application's approval. However, the FDA in 2016 rejected the application because of a lack of data. Otsuka Pharmaceutical had taken an interest in this technology and applied in 2015 for a new drug approval and patented the M圜ite trademark. Nonetheless, the aim of this technology has been to embed the sensor in a tablet or capsule along with the medication.
0 kommentar(er)
